BioSpace News Archive

Allermi announced today that its direct-to-patient telehealth service to provide customized multi-ingredient nasal sprays for the relief of allergy symptoms is now available.

Novarad Corporation announces a strategic alliance with a network of well-established specialty Neurosurgical and Spine distribution partners within the US.

BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services.

Ceribell, Inc. announced today that it has received Breakthrough Device Designation for its delirium indication from the United States Food and Drug Administration (FDA).

Clinical trials are the backbone of scientific progress; every new drug, device, or medical procedure must be investigated to ensure their safety and efficacy. Standard clinical trials – like randomized controlled trials (RCT) – often include large groups of people and are not tailored for personalized care.

Surgalign Holdings, Inc. announced two upcoming industry events it will be participating in and showcasing many of its latest spine and technology innovations.

argenx announced that during the extraordinary general meeting of shareholders held at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors.

Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference.

Akero Therapeutics, Inc. (Nasdaq: AKRO), will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).